RecruitingPhase 2NCT06984146
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Studying Classic Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Principal Investigator
- Andrey KaprinFSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation
- Intervention
- Nivolumab(drug)
- Enrollment
- 54 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation, Moscow, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06984146 on ClinicalTrials.govOther trials for Classic Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center
- RECRUITINGPHASE2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia
- RECRUITINGPHASE2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso
- RECRUITINGPHASE2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE4NCT06831370A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaTakeda